MMED

Mind Medicine Inc

MNMD.US mindmed.co
Price N/A
USD · NASDAQ
52-week range
8.77
15.49
Market Cap
1.46B
P/E Ratio
0.00
Forward P/E
0.00
Book Value
1.70
Div. Yield
N/A
% Institutions
41.65%
% Insiders
0.594%

1 Year

+127.5%

3 Year

+329.6%

10 Year

-42.9%
Description

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.

Company Information

Company Name
Mind Medicine Inc
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: CA60255C8850
CIK: 0001813814
CUSIP: 60365K108
Currency: USD
Full Time Employees: 74
Phone: 212 220 6633
Website: mindmed.co
Fiscal Year End: December
IPO Date: Mar 03, 2020
Description:

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.

Address:

One World Trade Center, New York, NY, United States, 10007

People

Directors & Officers

Name Title Year Born
Mr. Robert Barrow CEO & Director 1989
Mr. Mark R. Sullivan J.D. Chief Legal Officer & Corporate Secretary 1971
Dr. Daniel Rollings Karlin M.A., M.D. Chief Medical Officer 1980
Dr. Scott M. Freeman M.D. Co-Founder & Clinical Advisor 1957
Mr. Leonard Latchman Co-Founder NA
Ms. Brandi L. Roberts CPA, M.B.A. Chief Financial Officer 1974
Mr. Peter Mack Senior Vice President of Pharmaceutical Development & Operations NA
Ms. Beth Calitri Vice President of Corporate Communications NA
Ms. Stephanie Fagan Chief Corporate Affairs Officer NA
Dr. Gregg Pratt Ph.D. Chief Regulatory & Quality Assurance Officer NA

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Sep 25, 2025 Daniel Karlin N/A Sale 7.70K $9.77 $75.27K
Sep 25, 2025 Mark Sullivan N/A Sale 11.28K $9.77 $110.19K
Sep 25, 2025 Robert Barrow N/A Sale 25.80K $9.77 $252.04K
Jun 25, 2025 Daniel Karlin N/A Sale 7.85K $6.80 $53.37K
Jun 25, 2025 Mark Sullivan N/A Sale 11.49K $6.80 $78.14K
Jun 25, 2025 Robert Barrow N/A Sale 26.49K $6.80 $180.14K
Mar 25, 2025 Carrie Liao N/A Sale 2.35K $6.74 $15.82K
Mar 25, 2025 Daniel Karlin N/A Sale 6.84K $6.74 $46.07K
Mar 25, 2025 Robert Barrow N/A Sale 21.21K $6.74 $142.94K
Dec 26, 2024 Carrie Liao N/A Sale 2.27K $7.43 $16.89K
Dec 26, 2024 Dan Karlin N/A Sale 6.64K $7.43 $49.36K
Dec 26, 2024 Robert Barrow N/A Sale 19.11K $7.43 $141.96K

Shareholders

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
BlackRock Inc 5.80M Jun 30, 2025 7.63% $0.00 1.51%
COMMODORE CAPITAL LP 5.00M Jun 30, 2025 6.57% $2.29 10.50%
Blackstone Inc 3.59M Jun 30, 2025 4.71% $0.10 0.00%
Marshall Wace Asset Management Ltd 3.42M Jun 30, 2025 4.50% $0.03 31.93%
Driehaus Capital Management LLC 3.09M Jun 30, 2025 4.06% $0.16 -7.72%
Deep Track Capital, LP 2.50M Jun 30, 2025 3.29% $0.52 0.00%
Octagon Capital Advisors LP 2.13M Jun 30, 2025 2.80% $3.03 -29.42%
Vanguard Group Inc 1.81M Jun 30, 2025 2.38% $0.00 2.69%
State Street Corp 1.81M Jun 30, 2025 2.37% $0.00 -1.97%
Geode Capital Management, LLC 1.73M Jun 30, 2025 2.28% $0.00 4.00%
Awm Investment Company Inc 1.22M Jun 30, 2025 1.60% $0.88 0.62%
Ally Bridge Group (NY) LLC 726.17K Jun 30, 2025 0.95% $3.92 86.13%
Morgan Stanley - Brokerage Accounts 688.53K Jun 30, 2025 0.90% $0.00 4.34%
TANG CAPITAL MANAGEMENT LLC 600.20K Jun 30, 2025 0.79% $0.20 49.98%
Northern Trust Corp 599.24K Jun 30, 2025 0.79% $0.00 -6.77%
Charles Schwab Investment Management Inc 598.21K Jun 30, 2025 0.79% $0.00 6.20%
UBS Group AG 514.45K Jun 30, 2025 0.68% $0.00 376.22%
Woodline Partners LP 502.20K Jun 30, 2025 0.66% $0.02 -50.04%
Rosalind Advisors, Inc. 420.00K Jun 30, 2025 0.55% $1.29 0.00%
Wellington Management Company LLP 261.95K Jun 30, 2025 0.34% $0.00 15.95%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 iShares Russell 2000 ETF 1.83M 2.41% ▲ 0.00% Aug 31, 2025
2 Fidelity Small Cap Index 757.61K 1.00% ▲ 1.45% Jun 30, 2025
3 Vanguard Institutional Extnd Mkt Idx Tr 734.70K 0.97% ▼ 30.27% Jul 31, 2025
4 Heptagon Driehaus US Micro Cap Eq C$ Acc 702.75K 0.92% ▲ 5.97% Jul 31, 2025
5 iShares Russell 2000 Value ETF 461.23K 0.61% ▲ 0.00% Aug 31, 2025
6 Fidelity Extended Market Index 369.53K 0.49% ▲ 2.58% Jul 31, 2025
7 Vanguard Russell 2000 ETF 359.09K 0.47% ▼ 6.38% Jul 31, 2025
8 Schwab US Small-Cap ETF™ 326.88K 0.43% ▲ 0.25% Aug 30, 2025
9 Driehaus Micro Cap Growth USD 276.36K 0.36% ▲ 0.00% Jul 31, 2025
10 Driehaus Micro Cap Growth USD 276.36K 0.36% ▲ 0.00% Jul 31, 2025

Financial Highlights

Market Cap: $1.46B
EBITDA: $-151.67M
Book Value: $1.70
Earnings/Share: $-1.98
Profit Margin: 0.00%
Operating Margin: 0.00%
ROA (TTM): -33.95%
ROE (TTM): -85.59%
Revenue (TTM): $0.00
Revenue/Share (TTM): $0.00
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 0.00%

Valuation Metrics

Enterprise Value: $1.52B
Trailing P/E: 0.00
Forward P/E: 0.00

Shares Statistics

Shares Outstanding: 97.22M
Shares Float: 97.56M
% Insiders: 0.594%
% Institutions: 41.65%
Short % Float: 15.37%

Stock Price History

1 Year Price History

3 Years Price History

10 Years Price History

Financial Charts

Revenue, Net Income & Operating Cash Flow (Yearly)

Revenue, Net Income & Operating Cash Flow (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

Open full waterfall
Line Item
Step Type
Value
Revenue
adjust
$0.00
Cost of Goods Sold
adjust
$-527.00K
Gross Profit
subtotal
$-527.00K
SG&A
adjust
$-38.62M
R&D
adjust
$-65.30M
Operating Income
subtotal
$-103.92M
Other / Non-Operating Items
adjust
$-4.76M
Net Income
subtotal
$-108.68M

Earnings Per Share (EPS) History

Financial Ratios

📦 Raw API Data (JSON Explorer)

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about MNMD.US!